Stocks Health care INO
NASDAQ · Health careInovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $67.4M. In fiscal 2025 capital spending exceeded operating cash flow by $88.9M. At June 30, 2026 it held $31.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Inovio Pharmaceuticals, Inc.
- Net worth
- Inovio Pharmaceuticals, Inc. has a market value (market cap) of $156.1M at the latest share price, and shareholders' equity of $4.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $65.3K (-70.0% year on year), with a net loss of $84.9M. Over the 12 months to June 30, 2026: revenue $0, net loss $67.4M.
- Cash flow
- In fiscal 2025 operations used $88.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Inovio Pharmaceuticals, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Inovio Pharmaceuticals, Inc. does
Inovio Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65.3K | -$84.9M | -$1.81 | -$88.9M |
| 2024 | $217.8K | -$107.3M | -$3.95 | -$104.6M |
| 2023 | $832K | -$135.1M | -$6.09 | -$124.7M |
| 2022 | $10.3M | -$279.8M | -$14.07 | -$217.2M |
| 2021 | $1.8M | -$303.7M | -$17.45 | -$216.9M |
| 2020 | $7.4M | -$166.4M | -$12.88 | -$179.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INO ranks in Health care
Latest SEC filings
What Inovio Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 5, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 2, 2026
- October 6, 2026
- August 12, 2026
- August 12, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Inovio Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Kies PeterCFO | Exercised options | 8,700 | - |
| May 20, 2026 | Kies PeterCFO | Shares withheld for tax | 4,688 | $5.8K |
| May 20, 2026 | Humeau LaurentChief Scientific Officer | Exercised options | 6,027 | - |
| May 20, 2026 | Humeau LaurentChief Scientific Officer | Shares withheld for tax | 2,163 | $2.7K |
| May 20, 2026 | Shea Jacqueline ElizabethChief Executive Officer, Director | Exercised options | 28,296 | - |
| May 20, 2026 | Shea Jacqueline ElizabethChief Executive Officer, Director | Shares withheld for tax | 12,306 | $15.1K |
| May 20, 2026 | Sumner Michael JohnChief Medical Officer | Exercised options | 9,450 | - |
| May 20, 2026 | Sumner Michael JohnChief Medical Officer | Shares withheld for tax | 2,693 | $3.3K |
Who owns INO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.3% | August 6, 2026 |
| Janus Henderson Group PLC13G, passive | 9.99% | December 8, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 7, 2026 |
| Highbridge Capital Management LLC13G, passive | 8.2% | May 15, 2026 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 5.99% | February 17, 2026 |
| Vanguard Capital Management13G, passive | 5.05% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 102 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 8,454,797 | -884,817 |
| Jupiter Topco LLC | 5,171,053 | new |
| Vanguard Capital Management LLC | 3,650,562 | +749,354 |
| Boxer Capital Management, LLC | 2,844,994 | +474,872 |
| ADAR1 Capital Management, LLC | 2,143,910 | +673,802 |
| D. E. Shaw & Co., Inc. | 1,351,656 | -861,163 |
| Two Sigma Investments, LP | 1,239,778 | +849,394 |
| Eversept Partners, LP | 1,035,360 | 0 |
| Geode Capital Management, LLC | 802,751 | +1,247 |
| Millennium Management LLC | 796,107 | -614,738 |
| BlackRock, Inc. | 779,057 | +116,876 |
| Vanguard Fiduciary Trust Co | 480,769 | +88,703 |
| Caption Management, LLC | 478,950 | new |
| Renaissance Technologies LLC | 361,339 | -282,438 |
| State Street Corp | 336,610 | +40,300 |
| UBS Group AG | 262,320 | +12,670 |
| Quadrature Capital Ltd | 258,928 | new |
| Citadel Advisors LLC | 241,775 | -44,577 |
| Northern Trust Corp | 174,394 | -124,476 |
| Bridgeway Capital Management, LLC | 173,000 | 0 |
Insiders
5 insiders reported holding 330,328 shares in total, about $498.8K at the last price.
| Holder | Shares |
|---|---|
| Shea Jacqueline ElizabethChief Executive Officer, Director | 111,021 |
| Weiner David B.Director | 87,592 |
| Humeau LaurentChief Scientific Officer | 46,823 |
| Kies PeterCFO | 42,854 |
| Sumner Michael JohnChief Medical Officer | 42,038 |
Questions about INO
What does Inovio Pharmaceuticals, Inc. do?
Inovio Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as INO. Its shares trade on NASDAQ under the ticker INO.
What is Inovio Pharmaceuticals, Inc.'s net worth?
Inovio Pharmaceuticals, Inc. has a market value (market cap) of $156.1M at the latest share price, and shareholders' equity of $4.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Inovio Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $67.4M.
How much revenue does Inovio Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Inovio Pharmaceuticals, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Inovio Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from November 9, 2026.
When is Inovio Pharmaceuticals, Inc.'s next earnings report?
Inovio Pharmaceuticals, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INO with
Follow INO
Get an email when Inovio Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Inovio Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.